Tetrahydronapthyridine and related analogs for inhibiting YAP / TAZ-tead
Novel tetrahydronaphthyridine analogs effectively inhibit YAP/TAZ-TEAD transcription, addressing the limitations of existing therapies for YAP/TAZ-TEAD-mediated diseases by enhancing therapeutic efficacy and reducing side effects.
WO2024238763A2PCT designated stage expired Publication Date: 2024-11-21SPRINGWORKS THERAPEUTICS INC +2
Patent Information
- Application Number
- PCT/US2024/029643
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-16
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Technical Problem
Current therapies for diseases mediated by YAP/TAZ-TEAD activation, such as cancer and fibrosis, lack potency, are associated with side effects, and have suboptimal pharmacokinetic properties, necessitating the development of more effective inhibitors.
Method used
Development of novel tetrahydronaphthyridine and related analogs that specifically inhibit YAP/TAZ-TEAD transcriptional activity, offering enhanced potency and reduced toxicity.
Benefits of technology
These compounds effectively inhibit YAP/TAZ-TEAD transcription, providing a potent therapeutic option for treating various cancers and fibrotic diseases with improved safety and pharmacokinetic profiles.
✦ Generated by Eureka AI based on patent content.
Smart Images

Figure IMGF000032_0001 
Figure IMGF000042_0001 
Figure IMGF000043_0001
Abstract
The present disclosure relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of YAP / TAZ-TEAD transcription, yet more in particular for the prevention or treatment of cancer or fibrosis. The present disclosure also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Cited By
Azaindole and azaindoline compounds and uses thereof
WO2025231340A1
Methods and compositions for treating cancer using TEAD therapeutic agents
WO2026173532A1
